Bioneer Corporation
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analys… Read more
Bioneer Corporation (064550) - Total Liabilities
Latest total liabilities as of September 2025: ₩147.32 Billion KRW
Based on the latest financial reports, Bioneer Corporation (064550) has total liabilities worth ₩147.32 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioneer Corporation - Total Liabilities Trend (2011–2024)
This chart illustrates how Bioneer Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bioneer Corporation Competitors by Total Liabilities
The table below lists competitors of Bioneer Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sovereign Metals Limited
OTCQX:SVMLF
|
USA | $7.97 Million |
|
Iones Co. Ltd
KQ:114810
|
Korea | ₩45.16 Billion |
|
Savior Lifetec
TWO:4167
|
Taiwan | NT$420.16 Million |
|
First Savings Financial Group Inc
NASDAQ:FSFG
|
USA | $2.21 Billion |
|
29METALS Ltd
AU:29M
|
Australia | AU$595.63 Million |
|
Shenzhen Riland Industry Co
SHE:300154
|
China | CN¥923.44 Million |
|
Wintao Communications Co. Ltd
SHE:301139
|
China | CN¥1.42 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Bioneer Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioneer Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioneer Corporation (2011–2024)
The table below shows the annual total liabilities of Bioneer Corporation from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩105.29 Billion | +30.62% |
| 2023-12-31 | ₩80.61 Billion | +28.49% |
| 2022-12-31 | ₩62.74 Billion | +5.67% |
| 2021-12-31 | ₩59.37 Billion | +30.31% |
| 2020-12-31 | ₩45.56 Billion | -11.52% |
| 2019-12-31 | ₩51.49 Billion | +61.83% |
| 2018-12-31 | ₩31.82 Billion | +0.85% |
| 2017-12-31 | ₩31.55 Billion | -16.08% |
| 2016-12-31 | ₩37.59 Billion | +0.38% |
| 2015-12-31 | ₩37.45 Billion | +0.80% |
| 2014-12-31 | ₩37.16 Billion | -8.02% |
| 2013-12-31 | ₩40.40 Billion | +10.05% |
| 2012-12-31 | ₩36.71 Billion | +11.94% |
| 2011-12-31 | ₩32.79 Billion | -- |